Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | EDNRB | P24530 | 2/20 | 0.37 |
| ▸ | EDNRA | P25101 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30176364 | 0.93 | MEN1 (0.43) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL23886827 | 0.93 | MEN1 (0.43) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL30176352 | 0.92 | NPC1 (0.42) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL23886763 | 0.92 | NPC1 (0.42) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL23898552 | 0.90 | NPC1 (0.42) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL23898368 | 0.84 | KMT2A (0.41) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL30176272 | 0.82 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL23886942 | 0.82 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL23898666 | 0.82 | MEN1 (0.39) | NPC1RAB9AMEN1KMT2ASRD5A2 | |
| SCHEMBL23886885 | 0.80 | SCN9A (0.47) | NPC1RAB9AMEN1KMT2ASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339915-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| WO-2021203007-A1 | SUBSTITUTED 5-HYDROXYINDOLE COMPOUNDS AS MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339915-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | NPC1 369/4885RAB9A 3520/4885MEN1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.